Skip to main content
eScholarship
Open Access Publications from the University of California

Cellular senescence promotes adverse effects of chemotherapy and cancer relapse

  • Author(s): Demaria, M
  • O’Leary, MN
  • Chang, J
  • Shao, L
  • Liu, S
  • Alimirah, F
  • Koenig, K
  • Le, C
  • Mitin, N
  • Deal, AM
  • Alston, S
  • Academia, EC
  • Kilmarx, S
  • Valdovinos, A
  • Wang, B
  • De Bruin, A
  • Kennedy, BK
  • Melov, S
  • Zhou, D
  • Sharpless, NE
  • Muss, H
  • Campisi, J
  • et al.
Abstract

© 2017 American Association for Cancer Research. Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating cells nonspecifically, often with adverse reactions. In accord with prior work, we show that several chemotherapeutic drugs induce senescence of primary murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and systemic inflammation. Eliminating TIS cells reduced several short-and long-term effects of the drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence, and physical activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced fatigue was significantly greater in humans with increased expression of a senescence marker in T cells prior to chemotherapy. These findings suggest that senescent cells can cause certain chemotherapy side effects, providing a new target to reduce the toxicity of anticancer treatments. SIGNIFICANCE: Many genotoxic chemotherapies have debilitating side effects and also induce cellular senescence in normal tissues. The senescent cells remain chronically present where they can promote local and systemic inflammation that causes or exacerbates many side effects of the chemotherapy.

Main Content
Current View